NEW YORK, Sept. 6, 2016 /PRNewswire/ -- Growth in the clinical chemistry market will be driven by the low-to-mid-volume laboratory level, customers, according to Kalorama Information, and IVD vendors are adapting their models to compete in this segment. Clinical chemistries are common, first pass diagnostic tests and companies such as Roche, Abbott, Siemens and Danaher's Beckman Coulter lead the market. That means, the healthcare market researcher says, that the low- to medium-volume chemistry market, which includes small hospitals, satellite labs, clinics, and large doctor's offices, is where other competitors are aiming. The core lab IVD market is quantified in The Worldwide Market for In Vitro Diagnostic Tests, 10th Edition.
Clinical chemistries are performed using serum or plasma and are performed on analyzers with varying levels of automation depending on the test volume run at a particular test site. The market for routine clinical chemistries can be segmented in high and low volume users. Long eclipsed in apparent importance by molecular tests and esoteric immunoassays, several chemistries are making a mark in patient management. Routine clinical chemistry comprises 30 to 40 tests including: substrates, metabolites, electrolytes, blood gases, enzymes, urinalysis and lipids and can be divided into those performed for routine patient investigation and rapid response tests used to follow unstable hospitalized patients.
"Consolidation has forced the hands of vendors to seek low-to-mid volume labs as customers for revenue growth, and it's also a key segment for emerging market sales," said Bruce Carlson, Publisher of Kalorama Information. "In this kind of growthy middle segment, customers are both cost-conscious and expecting features."
Raritan, N.J.- based Ortho Clinical Diagnostics informed Kalorama in an interview at the American Association of Clinical Chemistry that middle-volume labs were its focus for revenue and installed base growth. The company's VITROS 250/350 Chemistry System supports this segment, but according to the company, a new system is in development that uses technologies from the company's large-volume 4600 models. The VITROS XT3400 is expected to deliver enhanced assay quality and productivity through the use of a digital imaging reflectometer. The VITROS XT 3400 System is expected to continue utilizing Ortho's VITROS MicroSlides, providing more than 40 routine chemistry tests. The company said it had added 1,300 employees since being spun off from J&J and ranked first in service performance by IMV Ltd's 2016 ServiceTrak reports. Ortho Clinical Diagnostics is the fifth-largest core lab company, and the first in blood typing according to Kalorama Information's Worldwide Market for In Vitro Diagnostic Tests, 10th Edition.
They are not alone, as many companies have products for the mid-volume chemistry market. In July 2015, Lexington, MA-based Sekisui Diagnostics launched the SK500 Chemistry System for the U.S. market. SK500 is designed for larger physicians' offices and small to moderate-sized hospital laboratories. The SK500 has a throughput of up to 580 tests/hour with ISE, 72 patient sample on-board capability, 36 onboard assays (+3 ISE) and primary tube sampling to meet the testing needs of small-to-moderate volume laboratories. Formerly Genzyme Diagnostics, the company was acquired by Sekisui Medical (Tokyo, Japan) in 2011 and the name was changed to Sekisui Diagnostics.
In addition, Randox's RX Daytona+ is a bench-top, fully automated, random access clinical chemistry analyzer capable of performing routine & specialized testing. Mindray's BA-800M chemistry analyzer, Beckman Coulter's UniCel DxC 600i and Carolina Liquid Chemistries CLC800 are other examples of products targeting the mid-volume level.
Kalorama Information's report, The Worldwide Market for In Vitro Diagnostic Tests, is a comprehensive look at the IVD industry and all of its segments - now in its 10th edition. The report has detailed market estimates of clinical chemistry, with breakouts for immunoassays performed on workstations, critical care, urinalysis and other segments. Competitors large and small are profiled. The report is global in scope and can be found at: http://www.kaloramainformation.com/Worldwide-Vitro-Diagnostic-10206771/.
Please link any media or news references to our reports or data to http://www.kaloramainformation.com/.
About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. Reports can be purchased through Kalorama's website and are also available on www.marketresearch.com and www.profound.com.
We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog at www.kaloramainformation.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/kalorama-ortho-clinical-diagnostics-sekisui-aim-at-growthy-middle-of-clinical-chemistry-market-300321873.html
SOURCE Kalorama Information